S-1/A: Vivos Therapeutics Files Amendment to S-1 Registration Statement for Share Resale
Amendment to Registration Statement
Vivos Therapeutics has filed an amendment to its S-1 registration statement, primarily to remove reliance on previously incorporated information, relating to the potential resale of common stock and warrants.
Summary
- Vivos Therapeutics has filed an amendment to its S-1 registration statement.
- The amendment is primarily to remove reliance on previously incorporated information.
- The document relates to the potential resale of up to 854,332 shares of common stock.
- These shares are comprised of shares underlying warrants issued in a private placement on December 22, 2024, and warrants issued to placement agents in connection with offerings on September 18, 2024 and December 22, 2024.
- The company will not receive any proceeds from the resale of these shares.
- However, the company would receive proceeds if the warrants are exercised for cash.
- The company intends to use any proceeds from warrant exercises for general corporate purposes and working capital.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, with no clear positive or negative sentiment. It is a factual description of a securities offering.
Risks
- The document indicates that the company will not receive any proceeds from the resale of the shares.
- The company is dependent on the exercise of warrants for cash proceeds.
- There is no assurance that any of the warrants will be exercised or that the company will receive any cash proceeds upon such exercise if cashless exercise is available.
Future Outlook
The document states that proceeds from the exercise of warrants will be used for general corporate purposes and working capital.
Industry Context
The document is a standard SEC filing related to the resale of securities, which is common in the financial industry.
Comparison to Industry Standards
- The document is a standard SEC filing for the resale of securities, which is a common practice for publicly traded companies.
- The structure of the offering, including the use of warrants and placement agents, is typical for companies seeking to raise capital.
- The document does not provide specific financial results that can be compared to industry standards.
Stakeholder Impact
- Existing shareholders may experience dilution if warrants are exercised.
- Potential investors may be interested in the opportunity to purchase shares.
- The company may benefit from additional capital if warrants are exercised.
Next Steps
- The company will use proceeds from warrant exercises for general corporate purposes and working capital.
- The company will continue to monitor the market and may conduct further offerings in the future.
Key Dates
| Date | Description |
|---|---|
| 2020-08-12 | Date of incorporation in Delaware |
| 2023-01-09 | Date of January 2023 Private Placement |
| 2023-02-28 | Date of acquisition of certain assets from Advanced Facialdontics, LLC |
| 2023-10-25 | Date of reverse stock split |
| 2023-10-30 | Date of securities purchase agreement for November 2023 private placement |
| 2023-11-02 | Date of November 2023 Private Placement |
| 2024-02-14 | Date of warrant inducement letter agreement |
| 2024-06-10 | Date of June 2024 Private Placement and Management Services Agreement with Seneca |
| 2024-09-18 | Date of September 2024 Registered Direct Offering |
| 2024-12-22 | Date of December 2024 Registered Direct Offering and Private Placement of the December 2024 Warrants |
| 2025-01-27 | Last reported sale price of the shares of our Common Stock as reported on Nasdaq |
| 2025-01-29 | Date of this prospectus |
Keywords
S-1, registration statement, common stock, warrants, resale, private placement, placement agent, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.